Viatris (NSDQ:VTRS) has received FDA approval for the first generic of Restasis (cyclosporine ophthalmic emulsion) eye drops. FDA first approved the drug, which was developed by Allergan, in 2003. Now marketed by AbbVie (NYSE:ABBV), Restasis sales are on the order of $1.2 billion annually. AbbVie recently noted in its projections for 2022 that it expected…